Therapeutics

[av_submenu which_menu=’center’ menu=” position=’center’ color=’main_color’ sticky=’true’ mobile=’disabled’ mobile_submenu=”]
[av_submenu_item title=’Menu Item 1′]
[av_submenu_item title=’Menu Item 2′]
[/av_submenu]

[av_image src=’https://www.ceremarkpharma.com/wp-content/uploads/2018/10/Ceremark-color-400.png’ attachment=’192′ attachment_size=’full’ align=’center’ styling=” hover=” link=” target=” caption=” font_size=” appearance=” overlay_opacity=’0.4′ overlay_color=’#000000′ overlay_text_color=’#ffffff’ animation=’no-animation’ custom_class=” admin_preview_bg=”][/av_image]

[av_hr class=’default’ height=’50’ shadow=’no-shadow’ position=’center’ custom_border=’av-border-thin’ custom_width=’50px’ custom_border_color=” custom_margin_top=’30px’ custom_margin_bottom=’30px’ icon_select=’yes’ custom_icon_color=” icon=’ue808′ av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=”]

[av_textblock size=” font_color=” color=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” custom_class=” admin_preview_bg=”]

Ceremark is developing a strong Intellectual Property portfolio to address the effects of human Traumatic Brain Injury (TBI).  In conjunction with an affiliate scientific company, a family of patent applications, with both domestic and international protection, are possessed with patent protection pending. Several strong putative agents, based upon laboratory and human research regarding TBI, neurodegeneration and CTE are poised to enter pre-clinical toxicology investigations leading to Phase I clinical studies.

[/av_textblock]

[av_hr class=’default’ height=’50’ shadow=’no-shadow’ position=’center’ custom_border=’av-border-thin’ custom_width=’50px’ custom_border_color=” custom_margin_top=’30px’ custom_margin_bottom=’30px’ icon_select=’yes’ custom_icon_color=” icon=’ue808′ av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=”]

[av_image src=’https://www.ceremarkpharma.com/wp-content/uploads/2020/10/Screen-Shot-2020-10-18-at-9.33.04-AM-1030×410.png’ attachment=’322′ attachment_size=’large’ align=’center’ styling=” hover=” link=” target=” caption=” font_size=” appearance=” overlay_opacity=’0.4′ overlay_color=’#000000′ overlay_text_color=’#ffffff’ animation=’no-animation’ custom_class=” admin_preview_bg=”][/av_image]

[av_hr class=’default’ height=’50’ shadow=’no-shadow’ position=’center’ custom_border=’av-border-thin’ custom_width=’50px’ custom_border_color=” custom_margin_top=’30px’ custom_margin_bottom=’30px’ icon_select=’yes’ custom_icon_color=” icon=’ue808′ av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=”]

[av_gallery ids=’277,278,303′ style=’thumbnails’ preview_size=’portfolio_small’ crop_big_preview_thumbnail=’avia-gallery-big-crop-thumb’ thumb_size=’portfolio’ columns=’5′ imagelink=’lightbox’ lazyload=’avia_lazyload’ custom_class=” admin_preview_bg=”]

[av_hr class=’default’ height=’50’ shadow=’no-shadow’ position=’center’ custom_border=’av-border-thin’ custom_width=’50px’ custom_border_color=” custom_margin_top=’30px’ custom_margin_bottom=’30px’ icon_select=’yes’ custom_icon_color=” icon=’ue808′ av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=”]

[av_textblock size=” font_color=” color=” av-medium-font-size=” av-small-font-size=” av-mini-font-size=” custom_class=” admin_preview_bg=”]

• Several pharmacological agents have been shown to regulate protective mechanisms in the central nervous system against traumatic brain injuries, as well as  pathological processes that result in cell death associated with or triggered by the presence of phosphylated tau and beta amyloid proteins.

• Preclinical studies have shown that several agents:

  • Are an endoplasmic reticulum stress inhibitor, associated with improved cognitive performance in animals following repetitive TBI.

  • There are three primary mechanisms of action whereby repetitive TBI actives ER stress which can result in damaged proteins and activating apoptosis.

  • Exert a cytoprotective effect to attenuate ER stress-induced neuronal cell death.

• Tested in preclinical animal models, CereMark proposes studies in patients with both CTE and Alzheimer’s Disease leading to a Phase 1 trial in the  regulatory approval pathway to eventual NDA and commercialization as acute and chronically administered neurodegenerative prophylactic or therapeutic treatments.

[/av_textblock]

[av_hr class=’default’ height=’50’ shadow=’no-shadow’ position=’center’ custom_border=’av-border-thin’ custom_width=’50px’ custom_border_color=” custom_margin_top=’30px’ custom_margin_bottom=’30px’ icon_select=’yes’ custom_icon_color=” icon=’ue808′ av-desktop-hide=” av-medium-hide=” av-small-hide=” av-mini-hide=”]